Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
May 3, 2022
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study
Yumeng Zhang, Lauren Duncanson, Jason Brayer, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 22, 2005
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects
Lyudmila Burdelya, Maciej Kujawski, Guilian Niu, et al.
Nature Medicine
|
January 2, 2004
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Tianhong Wang, Guilian Niu, Marcin Kortylewski, et al.
Journal of Geriatric Oncology
|
September 18, 2023
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
Othman Salim Akhtar, Ba Aqeel Sheeba, Farhan Azad, et al.
British Journal of Haematology
|
March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Taiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Cancer Cell
|
October 10, 2025
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Francesco Di Meo, Francesca Albano, Annamaria Cesarano, et al.
Transplantation and Cellular Therapy
|
December 20, 2023
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Othman S Akhtar, Karnav Modi, Jongphil Kim, et al.
American Journal of Hematology
|
August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
Irene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Clinical Lymphoma, Myeloma & Leukemia
|
May 3, 2022
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study
Yumeng Zhang, Lauren Duncanson, Jason Brayer, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 22, 2005
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects
Lyudmila Burdelya, Maciej Kujawski, Guilian Niu, et al.
Nature Medicine
|
January 2, 2004
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Tianhong Wang, Guilian Niu, Marcin Kortylewski, et al.
Journal of Geriatric Oncology
|
September 18, 2023
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
Othman Salim Akhtar, Ba Aqeel Sheeba, Farhan Azad, et al.
British Journal of Haematology
|
March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Taiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Cancer Cell
|
October 10, 2025
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Francesco Di Meo, Francesca Albano, Annamaria Cesarano, et al.
Transplantation and Cellular Therapy
|
December 20, 2023
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Othman S Akhtar, Karnav Modi, Jongphil Kim, et al.
American Journal of Hematology
|
August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
Irene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Page
of 3